Standardized CT-based criteria used for lymphoma staging and follow-up and the current role of FDG-PET are reviewed. The current CT-based International Workshop Criteria (IWC) still have the main advantage of representing standardized criteria allowing comparability of clinical trials in patients with lymphoma. However, functional imaging with integrated IWC and FDG-PET provide more accurate response assessment, and challenge the current paradigm. Although integration of FDG-PET in IWC requires validation in a prospective trial with a large number of patients, new long-term clinical and therapeutic trials probably need to be designed using these new and hopefully standardized functional criteria. This potentially could allow a more risk-adapted approach to the treatment of aggressive lymphoma: intensive (reinforced) therapies for non-responders vs. less intensive therapies for good responders with the main goal of improved clinical outcome.

Author

Alain Rahmouni, Alain Luciani and Emmanuel Itti

Contact Details

Corresponding address:
Alain Rahmouni, MD,
Imagerie Medicale,
CHU Henri Mondor, 51,
avenue du Marechal de Lattre de Tassigny,
94010 Creteil cedex, France.

Reference

ICIS Cancer Imaging Volume 5 Special Issue A
DOI: 10.1102/1470-7330.2005.0037

Date Posted

24 November 2005

Print PDF

Size

979.32 KB

Minimum Estimated Download Times

ADSL 2Mb/s (Broadband):	3 seconds
ADSL 512Kb/s (Broadband):	15 seconds
64 Kb/s (ISDN):	2 minutes 2 seconds
33.3 Kb/s (Typical Modem):	3 minutes 55 seconds

Screen PDF

Size

276.13 KB

Minimum Estimated Download Times

ADSL 2Mb/s (Broadband):	1 second
ADSL 512Kb/s (Broadband):	4 seconds
64 Kb/s (ISDN):	34 seconds
33.3 Kb/s (Typical Modem):	1 minute 6 seconds

No part of this publication or site may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the Publisher, e-MED Limited, Permissions, PO Box 61053, London, SE16 7YZ. Tel: +44 (0)207 719 8989 Fax: +44 (0)560 126 4446, permissions@cancerimaging.org.